Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

NCT04643002 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04643002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04643002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 25, 2021
Completion date
April 20, 2028
Enrollment
258 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma refractory